Brixen K, Nielsen H K, Mosekilde L, Flyvbjerg A
University Department of Endocrinology, Aarhus County Hospital, Denmark.
J Bone Miner Res. 1990 Jun;5(6):609-18. doi: 10.1002/jbmr.5650050610.
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo. Serum somatomedin C rose during treatment (p less than 0.001) but was not significantly different from baseline at day 14. The fasting urinary hydroxyproline/creatinine (p less than 0.001) and calcium/creatinine ratios (p less than 0.01) increased during treatment and remained elevated for 4 and 2 weeks, respectively. Serum bone gamma-carboxyglutamic acid-containing protein (BGP) increased during treatment (p less than 0.001) and remained elevated for 6 months (p less than 0.02). Serum bone alkaline phosphatase (B-AP), after an initial fall in the treatment period (p less than 0.001), increased slightly in the following months (p less than 0.01). In the rhGH group BMC was significantly higher than the prestudy value at day 14 (p less than 0.05) but was unaltered at the end of study. The simultaneous increase in markers of bone resorption and formation during rhGH treatment followed by a decline in resorption parameters within a few weeks and the prolonged effect on BGP and B-AP demonstrate that rhGH treatment stimulates osteoblasts and activates bone remodeling.
在20名年龄在22至31岁的正常男性志愿者中，研究了重组人生长激素（rhGH）对骨转换生化标志物和骨矿物质含量（BMC）的影响。这些志愿者被随机分为两组，一组接受rhGH治疗（0.1 IU/kg皮下注射，每日两次）7天，另一组接受安慰剂治疗。治疗期间血清生长调节素C升高（p<0.001），但在第14天时与基线水平无显著差异。空腹尿羟脯氨酸/肌酐比值（p<0.001）和钙/肌酐比值（p<0.01）在治疗期间升高，分别在4周和2周内保持升高。血清骨γ-羧基谷氨酸蛋白（BGP）在治疗期间升高（p<0.001），并在6个月内保持升高（p<0.02）。血清骨碱性磷酸酶（B-AP）在治疗初期下降（p<0.001），随后几个月略有升高（p<0.01）。在rhGH组中，第14天时BMC显著高于研究前值（p<0.05），但在研究结束时未发生改变。rhGH治疗期间骨吸收和形成标志物同时增加，随后几周内吸收参数下降，以及对BGP和B-AP的长期影响表明，rhGH治疗可刺激成骨细胞并激活骨重塑。
